Keros Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Keros Therapeutics, Inc. (KROS) had Deferred Tax Assets, Operating Loss Carryforwards of $35.14 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $35.14M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $45.08M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $36.24M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $37.69M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $35.14M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $45.08M 10-K · filed 2026-03-04 | |
| 2023-12-31 | $36.24M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $37.69M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $27.83M 10-K · filed 2023-03-03 | $23.72M 10-K · filed 2022-03-09 |
| 2020-12-31 | $10.32M 10-K · filed 2022-03-09 | |
| 2019-12-31 | $3.13M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |